Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7635-7641

  Goetz, Alexander W ^a   Van der Kuip, Heiko ^a   Aulitzky, Walter E ^b   Maya, Ruth ^c   Oren, Moshe ^c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; CASPASE; IMATINIB; INTERLEUKIN 2; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

APOPTOSIS; B-LYMPHOCYTES; CELL LINE; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; DOWN-REGULATION; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOID, CHRONIC; MEGAKARYOCYTES; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIENZYME COMPLEXES; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIMIDINES; TRANSFECTION;

EID: 0035886865     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. The bcr-abl gene in chronic myelogenous leukaemia
2. BCR/ABL signal transduction
3. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
4. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
5. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
6. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors
7. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras
8. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein
9. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc
10. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X
11. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL
12. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2
13. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
14. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf
15. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines
16. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients
17. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl
18. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
19. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia
20. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia
21. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia
22. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia
23. Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis
24. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML
25. Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation
26. c-Abl neutralizes the inhibitory effect of Mdm2 on p53
27. p19(Arf) induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation
28. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal
29. Growth factor modulation of p53-mediated growth arrest versus apoptosis
30. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells
31. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes
32. MDM2 function
33. Functions of the Mdm2 oncoprotein
34. Mdm2: The ups and downs
35. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
36. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
37. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene
38. p53, the cellular gatekeeper for growth and division
39. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
40. Induction of Mdm2 and enhancement of cell survival by bFGF
41. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis
42. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes
43. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF
44. Interaction of the receptor tyrosine kinase p145c-kit with the p210Bcr-Abl kinase in myeloid cells
45. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
46. Mapping of the p53 and mdm-2 interaction domains
47. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
48. Regulation of the p53 tumor suppressor protein
49. The loss of mdm2 induces p53-mediated apoptosis
50. Signal transduction by wild-type and leukemogenic Abl proteins
51. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
52. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase
53. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
54. BCR-ABL: An anti-apoptosis gene in chronic myelogenous leukemia
55. Role of Bcr-Abl kinase in resistance to apoptosis
56. Molecular abnormalities in chronic myeloid leukemia: Deregulation of cell growth and apoptosis
57. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells
58. The human MDM-2 oncogene is overexpressed in leukemias
59. Over-expression of the MDM2 gene is found in some cases of haematological malignancies
60. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin
61. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas
62. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene
63. Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells
64. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein
65. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia
66. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
67. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1